Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerRodrigo Sánchez-Bayona, Pablo Tolosa, Laura Lema et al.|Cancer Research|2022Cited by 4
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Isabel García-Fructuoso et al.|Breast Cancer Research and Treatment|2026Cited by 0